Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to investigate the pharmacokinetics (PK) similarity of Bmab1700 (an intended nivolumab biosimilar), compared with United States (US)-licensed Opdivo, in participants after complete surgical removal of melanoma.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Osoby w wieku 18 lat lub starsze, które rozumieją i chcą wziąć udział w badaniu.
- •Osoby z czerniakiem w zaawansowanym stadium (IIB, IIC, III lub IV), który został całkowicie usunięty podczas operacji.
- •Osoby, u których czerniak został całkowicie usunięty operacyjnie w ciągu ostatnich 12 tygodni.
- •Osoby, u których po operacji nie stwierdzono obecności czerniaka, co potwierdzono badaniami.
- •Osoby, których ogólny stan zdrowia pozwala na udział w badaniu (oceniany przez lekarza).
✗ Disqualifies
- •Osoby z historią czerniaka oka lub błony naczyniowej oka.
- •Osoby z aktywnymi lub podejrzewanymi chorobami autoimmunologicznymi (np. chorobami, w których układ odpornościowy atakuje własne tkanki).
- •Osoby, które były leczone na choroby autoimmunologiczne w ciągu ostatnich 2 lat.
- •Osoby z inną aktywną chorobą nowotworową (poza czerniakiem) w ciągu ostatnich 3 lat, chyba że była to choroba wczesnego stadium, która została wyleczona.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 25, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (46)
Biocon Investigational Site
Bento Gonçalves, Brazil
Biocon Investigational Site
Ijuí, Brazil
Biocon Investigational Site
Pará, Brazil
Biocon Investigational Site
Porto Alegre, Brazil
Biocon Investigational Site
Rio de Janeiro, Brazil
Biocon Investigational Site 1
Santa Catarina, Brazil
Biocon Investigational Site 2
Santa Catarina, Brazil
Biocon Investigational Site
Santa Catarina, Brazil
Biocon Investigational Site 1
São Paulo, Brazil
Biocon Investigational Site 2
São Paulo, Brazil
Biocon Investigational Site
São Paulo, Brazil
Biocon Investigational Site
Providencia, Chile
Biocon Investigational Site
Recoleta, Chile
Biocon Investigational Site 1
Santiago, Chile
Biocon Investigational Site
Santiago, Chile
Biocon Investigational Site
Batumi, Georgia
Biocon Investigational Site
Kutaisi, Georgia
Biocon Investigational Site 1
Tbilisi, Georgia
Biocon Investigational Site 3
Tbilisi, Georgia
Biocon Investigational Site 4
Tbilisi, Georgia
Biocon Investigational Site 5
Tbilisi, Georgia
Biocon Investigational Site
Tbilisi, Georgia
Biocon Investigational Site
Chisinau, Moldova
Biocon Investigational Site
Bucharest, Romania
Site 26
Cluj-Napoca, Romania
Biocon Investigational Site
Craiova, Romania
Biocon Investigational Site 1
Belgrade, Serbia
Biocon Investigational Site
Belgrade, Serbia
Biocon Investigational Site
Kamenitz, Serbia
Biocon Investigational Site
Kragujevac, Serbia
Biocon Investigational Site
Niš, Serbia
Biocon Investigational Site
George, South Africa
Biocon Investigational Site 1
Johannesburg, South Africa
Biocon Investigational Site
Johannesburg, South Africa
Biocon Investigational Site 1
Barcelona, Spain
Biocon Investigational Site
Barcelona, Spain
Biocon Investigational Site
Madrid, Spain
Biocon Investigational Site
Murcia, Spain
Biocon Investigational Site
Sabadell, Spain
Biocon Investigational Site 1
Seville, Spain
Biocon Investigational Site
Seville, Spain
Biocon Investigational Site
Ankara, Turkey (Türkiye)
Biocon Investigational Site
Bornova, Turkey (Türkiye)
Biocon Investigational Site
Konak, Turkey (Türkiye)
Biocon Investigational Site
Ivano-Frankivsk, Ukraine
Biocon Investigational Site
Kyiv, Ukraine
Trial contact
Dr. Gursharan Singh, MBBS; PhD Pharm Med; LLM-IP
Rajesh CN
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/26/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.